retagliptin + metformin

Retagliptin + metformin is a **fixed-dose combination** of two oral antihyperglycemic agents used for the treatment of type 2 diabetes mellitus. **Retagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing incretin levels, thereby stimulating insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. **Metformin** is a biguanide that lowers blood glucose primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. The combination is intended to provide additive glycemic control in patients who have inadequate control on metformin alone[4]. The combination is under study and not widely marketed globally as a fixed-dose product, and the available evidence is primarily from clinical trials in China[4].

Brand names

瑞泽唐 + metformin

Other names

Retgliptin/Metformin